Challenges in Implementing Hospice Clinical Trials: Preserving Scientific Integrity While Facing Change

被引:16
|
作者
Oliver, Debra Parker [1 ]
Washington, Karla T. [1 ]
Demiris, George [2 ]
White, Patrick [3 ]
机构
[1] Univ Missouri, Dept Family & Community Med, One Univ Dr,MA 306G, Columbia, MO 65203 USA
[2] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[3] Washington Univ, Sch Med, Dept Internal Med, Div Palliat Med,Palliat Med & Support Care, St Louis, MO 63110 USA
关键词
Hospice clinical trial; cluster crossover designs in hospice; pragmatic randomized clinical trials; CLUSTER RANDOMIZATION; CARE; DESIGN;
D O I
10.1016/j.jpainsymman.2019.09.028
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background/Aims. Numerous changes can occur between the original design plans for clinical trials, the submission of funding proposals, and the implementation of the clinical trial. In the hospice setting, environmental changes can present significant obstacles, which require changes to the original plan designs, recruitment, and staffing. The purpose of the study was to share lessons and problem-solving strategies that can assist in future hospice trials. Methods. This study uses one hospice clinical trial as an exemplar to demonstrate challenges for clinical trial research in this setting. Using preliminary data collected during the first months of a trial, the research team details the many ways their current protocol reflects changes from the originally proposed plans. Experiences are used as an exemplar to address the following questions: 1) How do research environments change between the initial submission of a funding proposal and the eventual award? 2) How can investigators maintain the integrity of the research and accommodate unexpected changes in the research environment? Results. The changing environment within the hospice setting required design, sampling, and recruitment changes within the first year. The decision-making process resulted in a stronger design with greater generalization. As a result of necessary protocol changes, the study results are positioned to be translational following the study conclusion. Conclusion. Researchers would do well to review their protocol and statistics early in a clinical trial. They should be prepared for adjustments to accommodate market and environmental changes outside their control. Ongoing data monitoring, specifically related to recruitment, is advised. (C) 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 39 条
  • [31] Not at all simple: The lay language summary of oncology clinical trials results. Challenges in implementing the new EU regulation (536/2014)
    Nottbohm, A.
    Weiss-Haljiti, C.
    Schindler, T. M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [32] Ensuring biological sample integrity from collection to analysis for LC-MS workflows: case studies illustrating challenges in clinical trials
    Anderson, Melanie
    [J]. BIOANALYSIS, 2019, 11 (20) : 1859 - 1866
  • [33] Challenges in implementing and managing clinical trials in developing countries: lessons learned by the national cancer institute's (NCI) AIDS malignancy consortium (AMC)
    Wirth, Megan
    Blumberg, Dikla
    Mosby-Griffin, Kimberly
    Vena, Don
    [J]. TRIALS, 2017, 18
  • [34] Ensuring safety, implementation and scientific integrity of clinical trials: lessons from the Criminal Justice–Drug Abuse Treatment Studies Data and Safety Monitoring Board
    Redonna K. Chandler
    Michael L. Dennis
    Nabila El-Bassel
    Robert P. Schwartz
    Gary Field
    [J]. Journal of Experimental Criminology, 2009, 5 : 323 - 344
  • [35] Ensuring safety, implementation and scientific integrity of clinical trials: lessons from the Criminal Justice-Drug Abuse Treatment Studies Data and Safety Monitoring Board
    Chandler, Redonna K.
    Dennis, Michael L.
    El-Bassel, Nabila
    Schwartz, Robert P.
    Field, Gary
    [J]. JOURNAL OF EXPERIMENTAL CRIMINOLOGY, 2009, 5 (03) : 323 - 344
  • [36] More than the emperor's new clothes: enhancing meaningful patient and public involvement in trial oversight committees through qualitative research with eight clinical trials facing challenges
    Nicolson, Alex
    Daykin, Anne
    Coulman, Karen
    Clement, Clare
    Cramer, Helen
    Gamble, Carrol
    Macefield, Rhiannon
    McCann, Sharon
    Shorter, Gillian W.
    Sydes, Mathew R.
    [J]. TRIALS, 2017, 18
  • [37] Implementing substance abuse group therapy clinical trials in real-world settings: Challenges and strategies for participant recruitment and therapist training in the Women's Recovery Group Study
    Greenfield, Shelly F.
    Crisafulli, Michele A.
    Kaufman, Julia S.
    Freid, Cathryn M.
    Bailey, Genie L.
    Connery, Hilary S.
    Rapoza, Michelle
    Rodolico, John
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2014, 23 (03): : 197 - 204
  • [39] Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
    Levey, Andrew S.
    Gansevoort, Ron T.
    Coresh, Josef
    Inker, Lesley A.
    Heerspink, Hiddo L.
    Grams, Morgan E.
    Greene, Tom
    Tighiouart, Hocine
    Matsushita, Kunihiro
    Ballew, Shoshana H.
    Sang, Yingying
    Vonesh, Edward
    Ying, Jian
    Manley, Tom
    de Zeeuw, Dick
    Eckardt, Kai-Uwe
    Levin, Adeera
    Perkovic, Vlado
    Zhang, Luxia
    Willis, Kerry
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (01) : 84 - 104